Healthcare stocks were in focus after CLSA highlighted a strong budgetary push for the sector in FY27, while noting that the upside for pharmaceutical companies remains limited.
According to CLSA, healthcare allocation has increased 33% year-on-year in FY27, reflecting a significant policy focus on the sector. The brokerage said the government’s emphasis spans medical tourism, biopharma development, expansion of the talent pool, and healthcare infrastructure creation.
CLSA noted that customs duty cuts are positive for multinational pharmaceutical companies, improving cost structures and competitiveness. However, the brokerage said the benefits for Indian pharmaceutical manufacturers are likely to remain limited despite the broader budgetary support.
Within the healthcare space, CLSA highlighted that large hospital chains are expected to emerge as the key beneficiaries of the increased allocation and policy focus.
Disclaimer: This article is based solely on brokerage inputs provided by the user. The views expressed are those of the brokerage and do not constitute investment advice or recommendations by the publication.
